SUPN Q4 2023 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$164M-1.8% YoY

Gross Profit

$145M88.1% margin

Operating Income

-$996,000-0.6% margin

Net Income

$1M0.7% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+6.8%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$45M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$356M

Stockholders' Equity

$922M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$167M	-1.8%
Gross Profit	$145M	$144M	+0.2%
Operating Income	-$996,000	$34M	-102.9%
Net Income	$1M	$25M	-95.4%

Revenue Segments

Product

$156M49%

Qelbree

$46M14%

GOCOVRI

$32M10%

Oxtellar X R

$31M10%

Trokendi Xr

$20M6%

APOKYN

$19M6%

Royalty

$8M3%

Manufactured Product, Other

$8M3%